2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt
Based on 90 publication(s) in Google Scholar
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt (ADU-S100 disodium salt) is an activator of stimulator of interferon genes (STING).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.46%
- CAS 番号: 1638750-95-4
- 分子式: C20H22N10Na2O10P2S2
- 分子量:734.51
-
保管条件:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
MedChemExpress(MCE)の使用を引用している文献 2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt
More- Nature. 2026 Feb;650(8100):242-250. [Abstract]
- Nature. 2023 Apr;616(7958):806-813. [Abstract]
- Science. 2026 May 7;392(6798):eadx1893. [Abstract]
- Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]
- Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12. [Abstract]
- Cancer Cell. 2020 Mar 16;37(3):289-307.e9. [Abstract]
- Nat Nanotechnol. 2021 Nov;16(11):1260-1270. [Abstract]
- Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]
- Immunity. 2025 Nov 11;58(11):2670-2684.e10. [Abstract]
- Cell Mol Immunol. 2025 Dec;22(12):1549-1566. [Abstract]
- Nat Cell Biol. 2026 Mar 6. [Abstract]
- Nat Cell Biol. 2024 Sep;26(9):1585-1596. [Abstract]
- Adv Funct Mater. 2025 Nov 11.
- Nat Commun. 2024 Nov 15;15(1):9934. [Abstract]
- Nat Commun. 2023 Oct 2;14(1):6132. [Abstract]
- Nat Commun. 2023 Sep 18;14(1):5666. [Abstract]
- Nat Commun. 2023 Mar 13;14(1):1390. [Abstract]
- Nat Commun. 2022 May 31;13(1):3022. [Abstract]
- Neuron. 2023 Jan 18;111(2):236-255.e7. [Abstract]
- Acta Pharm Sin B. 2025 Mar;15(3):1211-1229. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(16):e2414110. [Abstract]
- Adv Sci (Weinh). 2024 Nov 19:e2407222. [Abstract]
- J Clin Invest. 2024 Mar 19;134(10):e176748. [Abstract]
- Exp Hematol Oncol. 2026 Feb 7;15(1):21. [Abstract]
- Biomaterials. 2018 May;163:67-75. [Abstract]
- Mol Ther. 2025 Sep 22:S1525-0016(25)00761-0. [Abstract]
- J Control Release. 2025 Jan 14:379:327-343. [Abstract]
- J Exp Med. 2026 May 4;223(5):e20251796. [Abstract]
- Cell Rep Med. 2025 Jul 15;6(7):102239. [Abstract]
- J Immunother Cancer. 2024 Oct 14;12(10):e009803. [Abstract]
- J Immunother Cancer. 2019 Sep 18;7(1):252. [Abstract]
- Mater Today Bio. 2024 Mar 11:26:101018. [Abstract]
- Cancer Lett. 2026 May 1:645:218357. [Abstract]
- J Neuroinflammation. 2023 Apr 30;20(1):101. [Abstract]
- Environ Int. 2020 Oct;143:105949. [Abstract]
- Cell Death Dis. 2022 Jul 28;13(7):653. [Abstract]
- Sci China Life Sci. 2024 Dec;67(12):2664-2677. [Abstract]
- Genes Dis. 2024 Sep 15;12(2):101434. [Abstract]
- Cell Commun Signal. 2025 Feb 19;23(1):99. [Abstract]
- ACS Appl Mater Interfaces. 2025 Oct 15;17(41):56832-56845. [Abstract]
- ACS Appl Mater Interfaces. 2025 Feb 5;17(5):7395-7405. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58. [Abstract]
- J Autoimmun. 2024 Jun:146:103232. [Abstract]
- Oncoimmunology. 2025 Dec;14(1):2466305. [Abstract]
- JCI Insight. 2026 Mar 23;11(6):e197404. [Abstract]
- Cell Biol Toxicol. 2025 May 7;41(1):82. [Abstract]
- Front Immunol. 2023 Oct 13:14:1258691. [Abstract]
- Eur J Med Chem. 2023 Mar 15:250:115184. [Abstract]
- Eur J Med Chem. 2022 Dec 5:243:114796. [Abstract]
- Front Immunol. 2021 Jul 1:12:695056. [Abstract]
- Inflamm Res. 2023 Aug;72(8):1551-1565. [Abstract]
- Cancer Immunol Immunother. 2026 Feb 12;75(3):77. [Abstract]
- Commun Biol. 2021 Apr 22;4(1):497. [Abstract]
- Immunology. 2022 Dec;167(4):495-507. [Abstract]
- PLoS Pathog. 2026 Jan 13;22(1):e1013868. [Abstract]
- Int J Mol Sci. 2023 Dec 20;25(1):86. [Abstract]
- Mol Oncol. 2026 May 21. [Abstract]
- J Pharm Sci. 2025 Nov 17:104065. [Abstract]
- Acta Crystallogr D Struct Biol. 2020 Sep 1;76(Pt 9):889-898. [Abstract]
- Eur J Immunol. 2025 Dec;55(12):e70101. [Abstract]
- Cell Signal. 2025 Jun 16:111948. [Abstract]
- Mol Cell Biochem. 2021 Feb;476(2):1015-1024. [Abstract]
- Cancer Res Commun. 2024 Jan 16;4(1):118-133. [Abstract]
- J Innate Immun. 2026;18(1):126-136. [Abstract]
- PLoS One. 2020 Sep 10;15(9):e0237743. [Abstract]
- Chem Biodivers. 2024 Jul 12:e202401253. [Abstract]
- J Interferon Cytokine Res. 2025 Jan;45(1):29-37. [Abstract]
- The Medical College of Wisconsin. 2026.
- bioRxiv. 2026 Mar 26.
- Res Sq. 2026 Jan 22.
- Patent. US20250276085A1.
- Patent. US20250221932A1.
- Purdue University. 2024 Jul 20.
- bioRxiv. 2024 September 20.
- bioRxiv. 2024 September 07.
- Wayne State University. 2024.
- bioRxiv. 2024 May 14.
- Research Square Preprint. 2024 Apr 5.
- bioRxiv. 2024 Jan 23.
- University of Toronto. 2023 Jun.
- Patent. US20230062932A1.
- Patent. US20220395465A1.
- Patent. US20220162199A1.
- Research Square Preprint. 2022 Feb.
- bioRxiv. October 23, 2021.
- Research Square Preprint. 2022 Jan.
- Patent. US20210322327A1.
- Patent. US20210205468A1.
- University of Pittsburgh. School of Medicine. 2021 May 14.
- Patent. US20200146975A1
-
WB
-
Flow Cytometry
-
IHC
-
RT-PCR
-
In Vivo Efficacy Study
生物活性
STING[1]
2’3’-c-di-AM(PS)2 (Rp,Rp) shows enhanced type I IFN production over CDA in THP-1 human monocytes. In contrast, the dithio, mixed-linkage cyclic dinucleotide (CDN) derivatives (ML RR-CDA, ML RR-S2 CDG, and ML RR-S2 cGAMP) potently activate all five hSTING alleles, including the refractory hSTINGREF and hSTINGQ alleles. 2’3’-c-di-AM(PS)2 (Rp,Rp) induces the highest expression of IFN-β and the pro-inflammatory cytokines TNF-α, IL-6, and MCP-1 on a molar equivalent basis, as compared to endogenous ML cGAMP and the TLR3 agonist poly I:C. 2’3’-c-di-AM(PS)2 (Rp,Rp) is also found to induce aggregation of STING and induce phosphorylation of TBK1 and IRF3 in mouse bone marrow macrophage (BMM). 2’3’-c-di-AM(PS)2 (Rp,Rp) induces significantly higher levels of IFN-α when compared to ML cGAMP[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1638750-95-4
-
性状 Solid
-
分子量 734.51
-
分子式 C20H22N10Na2O10P2S2
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](O[P@@](OC[C@H]2O[C@@H](N3C(N=CN=C4N)=C4N=C3)[C@H](O)[C@@H]2O5)(S[Na])=O)[C@H](N6C(N=CN=C7N)=C7N=C6)O[C@@H]1CO[P@]5(S[Na])=O
-
別名
ADU-S100 disodium salt; MIW815 disodium salt; ML RR-S2 CDA disodium salt
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (90)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Feb;650(8100):242-250. PMID: 41372408 -
Nature
2023 Apr;616(7958):806-813. PMID: 36991128 -
Science
2026 May 7;392(6798):eadx1893. PMID: 42096576 -
Cancer Cell
2024 May 13;42(5):850-868.e9. PMID: 38670091
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]
Cell viability assays of isogenic NTC, Trp53 KO, and Bak/Bax KO Eμ-Myc lymphoma cell lines treated with S63845 in combination with ADU-S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt, 2-10 μg/mL), MSA-2 (12-34 μM), or diABZI for 24 h.
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]
RT-qPCR for BH3-only and STING target genes in three independent isogenic NTC and Trp53 KO Em-Myc lymphoma cell lines treated with ADU-S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt, 10 μg/mL) for 24 h.Fold change is relative to the AH15A DMSO-treated NTC sample
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]
Cell viability assays of Eμ-Myc lymphoma cell lines treated with ADU-S100 (HY-12885A; AH15A/560: 0.5 μg/mL; 47A: 5 μg/mL) and/or TPCA-1 (HY-10074) for 24 h. Error bars represent SD for three independent experiments. Diagram illustrates how TPCA-1 acts to inhibit NF-κB signaling.
-
Cancer Cell
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. [Abstract]2023 Jun 12;41(6):1073-1090.e12. PMID: 37236195 -
Cancer Cell
2020 Mar 16;37(3):289-307.e9. PMID: 32183949 -
Nat Nanotechnol
Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. [Abstract]2021 Nov;16(11):1260-1270. PMID: 34594005 -
Nat Immunol
Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity. [Abstract]2025 Oct;26(10):1766-1780. PMID: 40897896
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]
2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) (10 μM) was added to the culture of KPC cells or endothelial cells (HUVEC) for indicated time, and the activation of STING signaling was analyzed by IRF3 Ser385 phosphorylation. The quantification of phosphorylated IRF3 was normalized by total IRF3. β-actin was used as a loading control.
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]
Leukocytes were isolated from peripheral blood or the peritoneum of normal mice and incubated in vitro with 7.2 μg/mL STING agonist 2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) for 2 h at 37 °C. Phosphorylation of IRF3 in leukocyte subsets (CD11b+ myeloid cells, CD3+ cells, CD19+ cells, and NK1.1+ cells) was detected by α-phospho-IRF3 Ser385 antibody staining. Cells were permeabilized using eBioscience™ Transcription Factor Staining Buffer Set before staining. The percent fraction of phospho-IRF3+ cells in each subset of blood or peritoneal leukocytes was determined by flow cytometry.
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]
STING agonist 2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) (2 μg intratumoral) and/or anti-LTβR agonistic antibody (100 μg, intraperitoneal (i.p.)) were administered to mice bearing subcutaneous KPC tumors as monotherapy or in combination as indicated. Immunohistochemistry of B cells (CD19, brown) and HEVs (MECA-79, magenta) shows numerous TLS induced by combination therapy (day 14). Scale bars, 1 mm (low magnification) and 100 μm (high magnification).
-
Immunity
Membrane integrity changes upon viral infection activate sphingomyelinase SMPDL3B to restrict cGAS-STING signaling via cGAMP degradation. [Abstract]2025 Nov 11;58(11):2670-2684.e10. PMID: 41175872 -
Cell Mol Immunol
Targeting MORF4L1-mediated DNA repair potentiates RT-induced antitumor immunity via cGAS-STING activation in hepatocellular carcinoma. [Abstract]2025 Dec;22(12):1549-1566. PMID: 41188483 -
Nat Cell Biol
Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS-STING and Toll-like receptors 3 and 4. [Abstract]2026 Mar 6. PMID: 41792265 -
Nat Cell Biol
mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer. [Abstract]2024 Sep;26(9):1585-1596. PMID: 39080411
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1585-1596. [Abstract]
Cell viability assays measuring 5-FU response in cGAS knockdown HCT116 cells stably expressing shRNA-resistant cGAS-S213D mutants or pretreated with 10 µM 2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) for 6 hours.
-
-
Nat Commun
2024 Nov 15;15(1):9934. PMID: 39548120 -
Nat Commun
Development of cyclopeptide inhibitors of cGAS targeting protein-DNA interaction and phase separation. [Abstract]2023 Oct 2;14(1):6132. PMID: 37783727 -
Nat Commun
Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection. [Abstract]2023 Sep 18;14(1):5666. PMID: 37723181 -
Nat Commun
Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. [Abstract]2023 Mar 13;14(1):1390. PMID: 36914658
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Mar 13;14(1):1390. [Abstract]
ADU-S100 (10 μM; 48 h; labeled as STING) enhances type I interferon gene expression in human dendritic cells (DCs).
-
Nat Commun
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. [Abstract]2022 May 31;13(1):3022. PMID: 35641483 -
Neuron
Driving axon regeneration by orchestrating neuronal and non-neuronal innate immune responses via the IFNγ-cGAS-STING axis. [Abstract]2023 Jan 18;111(2):236-255.e7. PMID: 36370710 -
Acta Pharm Sin B
Intravenous delivery of STING agonists using acid-sensitive polycationic polymer-modified lipid nanoparticles for enhanced tumor immunotherapy. [Abstract]2025 Mar;15(3):1211-1229. PMID: 40370538 -
Adv Sci (Weinh)
Tumor-Adhesive Chitosan-Derived Multi-Immune Agonist Unleashes Strong and Durable Anti-Cancer Immunity. [Abstract]2025 Apr;12(16):e2414110. PMID: 39999304
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(16):e2414110. [Abstract]
The relative mRNA expression of Ifnβ1 in 4T1 cells, MC38 cells and B16F10 cells after treatment with TACTIC, CS or ADU‐S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt, 20 µg/mL; 24 h) (n = 3).
-
Adv Sci (Weinh)
2024 Nov 19:e2407222. PMID: 39558862 -
J Clin Invest
STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. [Abstract]2024 Mar 19;134(10):e176748. PMID: 38502231 -
Exp Hematol Oncol
Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies. [Abstract]2026 Feb 7;15(1):21. PMID: 41654887 -
Biomaterials
2018 May;163:67-75. PMID: 29454236 -
Mol Ther
A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-α secretion in vivo. [Abstract]2025 Sep 22:S1525-0016(25)00761-0. PMID: 40988339
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Sep 22:S1525-0016(25)00761-0. [Abstract]
Titration of the agonist ADU-S100 in B16-OVA tumor model. OVA mRNA, 10 μg; C1, 1.6 mg; ADU-S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt): 10/20/40 μg. n=5 mice per group. The results indicated that the ADU-S100 dosage used (20 μg/mice) was likely optimal for the C1-mRNA+ADU-S100(nano) cancer vaccine.
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Sep 22:S1525-0016(25)00761-0. [Abstract]
Representative images of tumor-infiltrating CD8+ T cells by immunohistochemistry (left) and quantification of CD8+ T cells (right). Scale bars: 100 μm (upper) and 50 μm (lower). Tumor-infiltrating immune cell analysis by immunohistochemistry demonstrated that CD8+ T cells were enriched in tumors from Stingf/f Itgax-Cre– mice immunized with C1-OVA mRNA+ADU-S100(nano), but not in tumors from Stingf/f Itgax-Cre+ mice. The doses of mRNA vaccine per mouse in vivo were as follows: mRNA, 10 μg; C1, 1.6 mg; ADU-S100, 20 μg; c-di-AMP, 20 μg. C1-mRNA + ADU-S100(nano) was prepared by encapsulating ADU-S100 into the C1-mRNA nanovaccine during nanoparticle preparation.
-
J Control Release
2025 Jan 14:379:327-343. PMID: 39778743 -
J Exp Med
2026 May 4;223(5):e20251796. PMID: 41874365 -
Cell Rep Med
Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma. [Abstract]2025 Jul 15;6(7):102239. PMID: 40669448 -
J Immunother Cancer
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses. [Abstract]2024 Oct 14;12(10):e009803. PMID: 39401968 -
J Immunother Cancer
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. [Abstract]2019 Sep 18;7(1):252. PMID: 31533840 -
Mater Today Bio
2024 Mar 11:26:101018. PMID: 38516172 -
Cancer Lett
BRIP1-mediated RINT1 acetylation and NF-κB activation promote DNA repair and immunosuppressive microenvironment in lung adenocarcinoma. [Abstract]2026 May 1:645:218357. PMID: 41740833 -
J Neuroinflammation
STING controls opioid-induced itch and chronic itch via spinal tank-binding kinase 1-dependent type I interferon response in mice. [Abstract]2023 Apr 30;20(1):101. PMID: 37122031 -
Environ Int
Low-level contamination of deoxynivalenol: A threat from environmental toxins to porcine epidemic diarrhea virus infection. [Abstract]2020 Oct;143:105949. PMID: 32673909 -
Cell Death Dis
The interaction between STING and NCOA4 exacerbates lethal sepsis by orchestrating ferroptosis and inflammatory responses in macrophages. [Abstract]2022 Jul 28;13(7):653. PMID: 35902564 -
Sci China Life Sci
Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases. [Abstract]2024 Dec;67(12):2664-2677. PMID: 39190126 -
Genes Dis
Heavy mechanical force decelerates orthodontic tooth movement via Piezo1-induced mitochondrial calcium down-regulation. [Abstract]2024 Sep 15;12(2):101434. PMID: 39759122 -
Cell Commun Signal
Intrinsic STING of CD8 + T cells regulates self-metabolic reprogramming and memory to exert anti-tumor effects. [Abstract]2025 Feb 19;23(1):99. PMID: 39972350 -
ACS Appl Mater Interfaces
Synergistic Activation of the STING Pathway via a Mn(II)-Cross-Linked Gel Scaffold To Boost Antitumor Immunotherapy. [Abstract]2025 Oct 15;17(41):56832-56845. PMID: 41031586 -
ACS Appl Mater Interfaces
Programmable Porous Silicon Microparticles for Temporally Staged Drug Delivery in Combination Cancer Immunotherapy. [Abstract]2025 Feb 5;17(5):7395-7405. PMID: 39847761 -
Cell Mol Gastroenterol Hepatol
STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. [Abstract]2021;12(1):41-58. PMID: 33548597 -
J Autoimmun
Elevated type I IFN signalling directly affects CD8+ T-cell distribution and autoantigen recognition of the skeletal muscles in active JDM patients. [Abstract]2024 Jun:146:103232. PMID: 38692172 -
Oncoimmunology
Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses. [Abstract]2025 Dec;14(1):2466305. PMID: 39960413 -
JCI Insight
DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy. [Abstract]2026 Mar 23;11(6):e197404. PMID: 41869722 -
Cell Biol Toxicol
ELF4 improves sepsis-induced myocardial injury by regulating STING signaling-mediated T cells differentiation. [Abstract]2025 May 7;41(1):82. PMID: 40335763 -
Front Immunol
Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma. [Abstract]2023 Oct 13:14:1258691. PMID: 37901237 -
Eur J Med Chem
Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist. [Abstract]2023 Mar 15:250:115184. PMID: 36758305 -
Eur J Med Chem
S-acylthioalkyl ester (SATE)-based prodrugs of deoxyribose cyclic dinucleotides (dCDNs) as the STING agonist for antitumor immunotherapy. [Abstract]2022 Dec 5:243:114796. PMID: 36198216 -
Front Immunol
STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity. [Abstract]2021 Jul 1:12:695056. PMID: 34276686 -
Inflamm Res
STING-IFN-I pathway relieves incision induced acute postoperative pain via inhibiting the neuroinflammation in dorsal root ganglion of rats. [Abstract]2023 Aug;72(8):1551-1565. PMID: 37433890 -
Cancer Immunol Immunother
TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms. [Abstract]2026 Feb 12;75(3):77. PMID: 41677949 -
Commun Biol
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. [Abstract]2021 Apr 22;4(1):497. PMID: 33888863 -
Immunology
Host stimulator of interferon genes is essential for the efficacy of anti-programmed cell death protein 1 inhibitors in non-small cell lung cancer. [Abstract]2022 Dec;167(4):495-507. PMID: 35859099 -
PLoS Pathog
HIV-1 derived oligonucleotides induce a type I IFN/STING dependent immune suppression reversible by targeting IFNARI. [Abstract]2026 Jan 13;22(1):e1013868. PMID: 41529066 -
Int J Mol Sci
Dithioethanol (DTE)-Conjugated Deoxyribose Cyclic Dinucleotide Prodrugs (DTE-dCDNs) as STING Agonist. [Abstract]2023 Dec 20;25(1):86. PMID: 38203256 -
Mol Oncol
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer. [Abstract]2026 May 21. PMID: 42169500 -
J Pharm Sci
Phosphatidylserine blockade by dipicolylamine-zinc enhances chemoimmunotherapy of B16F10 melanoma. [Abstract]2025 Nov 17:104065. PMID: 41238189 -
Acta Crystallogr D Struct Biol
2020 Sep 1;76(Pt 9):889-898. PMID: 32876064 -
Eur J Immunol
Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. [Abstract]2025 Dec;55(12):e70101. PMID: 41410160 -
Cell Signal
Activation of STING pathway by mitochondrial fission negatively regulates adipogenic differentiation of 3 T3-L1 cells. [Abstract]2025 Jun 16:111948. PMID: 40532961 -
Mol Cell Biochem
Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response. [Abstract]2021 Feb;476(2):1015-1024. PMID: 33141310 -
Cancer Res Commun
Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers. [Abstract]2024 Jan 16;4(1):118-133. PMID: 38147007 -
J Innate Immun
Pharmacological Stimulator of Interferon Genes Activation Enhances Autophagy-Mediated Clearance ofMycobacterium tuberculosis in Human Macrophages. [Abstract]2026;18(1):126-136. PMID: 41615864 -
PLoS One
2020 Sep 10;15(9):e0237743. PMID: 32911484 -
Chem Biodivers
Cyclopeptide Inhibitors Target the N-Terminal Tail of STING and Alleviate Autoinflammation. [Abstract]2024 Jul 12:e202401253. PMID: 38997793 -
J Interferon Cytokine Res
Stimulator of Interferon Genes Signal in Lung Cancer Regulates Differentiation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Via the Interferon Regulatory Factor 3/NF-κB Pathway. [Abstract]2025 Jan;45(1):29-37. PMID: 39772902 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
溶剤 & 溶解度
H2O : 100 mg/mL (136.15 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: ≥ 25 mg/mL (34.04 mM); Clear solution
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
プロトコル
Cryopreserved hPBMCs are thawed and 1×106 cells per well are plated in a 96 well plate in RPMI media supplemented with 10% FBS, 1% non-essential amino acids, 1% penicillin/streptomycin, L-glutamine, 10 mM HEPES buffer, 1 mM Sodium Pyruvate, 0.055 mM β-ME at 37°C with 5% CO2. Cells are stimulated with 10 μM ADU-S100 or ML cGAMP for 6 hours and supernatants are harvested. Supernatants are diluted 1:2 and assayed for IFN-α protein using Cytometric Bead Array (CBA) Human Flex Set. Data is collected using a FACSVerse cytometer and analyzed by FCAP Array Software[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
WT C57BL/6 mice are inoculated with 5×104 B16.F10 cells in the left flank (n=8). When tumor volumes are 100 mm3 mice receive three IT doses of either ML RR-S2 CDG (25 μg), ADU-S100 (50 μg), or HBSS as control. WT C57BL/6 mice are inoculated with 5×104 B16.F10 cells in the left flank (n=5). When tumor volumes are 100 mm3 they received three IT doses of ADU-S100 at 5, 25, 50 or 100 μg or HBSS as control. WT C57BL/6 mice are inoculated with 5×104 B16.F10 cells in the left flank (n=8). When tumor volumes are 100 mm3 they receive three IT doses of 100 μg ADU-S100 or HBSS as control. Treatments are administered on days 13, 17 and 20 and tumor measurements are taken twice weekly. Results are shown as percent survival by Log-rank (Mantel-Cox) test (A and C)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.3615 mL | 6.8073 mL | 13.6145 mL | 34.0363 mL |
| 5 mM | 0.2723 mL | 1.3615 mL | 2.7229 mL | 6.8073 mL | |
| 10 mM | 0.1361 mL | 0.6807 mL | 1.3615 mL | 3.4036 mL | |
| 15 mM | 0.0908 mL | 0.4538 mL | 0.9076 mL | 2.2691 mL | |
| 20 mM | 0.0681 mL | 0.3404 mL | 0.6807 mL | 1.7018 mL | |
| 25 mM | 0.0545 mL | 0.2723 mL | 0.5446 mL | 1.3615 mL | |
| 30 mM | 0.0454 mL | 0.2269 mL | 0.4538 mL | 1.1345 mL | |
| 40 mM | 0.0340 mL | 0.1702 mL | 0.3404 mL | 0.8509 mL | |
| 50 mM | 0.0272 mL | 0.1361 mL | 0.2723 mL | 0.6807 mL | |
| 60 mM | 0.0227 mL | 0.1135 mL | 0.2269 mL | 0.5673 mL | |
| 80 mM | 0.0170 mL | 0.0851 mL | 0.1702 mL | 0.4255 mL | |
| 100 mM | 0.0136 mL | 0.0681 mL | 0.1361 mL | 0.3404 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.